Quick Answer
Xenon Pharmaceuticals Inc. reported Long-Term Debt of $10.89 million for fiscal year 2019.
Xenon Pharmaceuticals Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2019 | $10.89M | -27.5% |
| 2018 | $15.01M | +146.0% |
| 2017 | $6.10M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2019 | $10.89M | -27.5% | -7.6% |
| September 30, 2019 | $11.79M | -20.8% | -10.7% |
| June 30, 2019 | $13.20M | +12.6% | -12.8% |
| March 31, 2019 | $15.14M | +176.5% | +0.8% |
| December 31, 2018 | $15.01M | +146.0% | +0.9% |
| September 30, 2018 | $14.89M | — | +27.0% |
| June 30, 2018 | $11.72M | — | +114.0% |
| March 31, 2018 | $5.48M | — | -10.3% |
- Xenon Pharmaceuticals Inc. showed a decrease of -27.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2017–2019 period, Xenon Pharmaceuticals Inc.’s long-term debt has grown by 78.4% (from $6.10 million to $10.89 million).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 1, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: